Mesoscale simulation of semiflexible chains. I. Endpoint distribution and chain dynamics.

J Chem Phys

Unilever Research Vlaardingen, P.O. Box 114, 3130 AC Vlaardingen, The Netherlands.

Published: June 2013

The endpoint distribution and dynamics of semiflexible fibers are studied by numerical simulation. A brief overview is given over the analytical theory of flexible and semiflexible polymers. In particular, a closed expression is given for the relaxation spectrum of wormlike chains, which determines polymer diffusion and rheology. Next a simulation model for wormlike chains with full hydrodynamic interaction is described, and relations for the bending and torsion modulus are given. Two methods are introduced to include torsion stiffness into the model. The model is validated by simulating single chains in a heat bath, and comparing the endpoint distribution of the chains with established Monte Carlo results. It is concluded that torsion stiffness leads to a slightly shorter effective persistence length for a given bending stiffness. To further validate the simulation model, polymer diffusion is studied for fixed persistence length and varying polymer length N. The diffusion constant shows crossover from Rouse (D [proportionality] N(-1)) to reptation behaviour (D [proportionality] N(-2)). The terminal relaxation time obtained from the monomer displacement is consistent with the theory of wormlike chains. The probability for chain crossing has also been studied. This probability is so low that it does not influence the present results.

Download full-text PDF

Source
http://dx.doi.org/10.1063/1.4808199DOI Listing

Publication Analysis

Top Keywords

endpoint distribution
12
wormlike chains
12
polymer diffusion
8
simulation model
8
torsion stiffness
8
persistence length
8
chains
6
mesoscale simulation
4
simulation semiflexible
4
semiflexible chains
4

Similar Publications

Systemically administered platelet-inspired nanoparticles to reduce inflammation surrounding intracortical microelectrodes.

Biomaterials

January 2025

Department of Biomedical Engineering, Case Western Reserve University, Cleveland, OH, United States; Advanced Platform Technology Center, Louis Stokes Cleveland Department of Veterans Affairs Medical Center, Cleveland, OH, United States. Electronic address:

Intracortical microelectrodes (IMEs) are essential for neural signal acquisition in neuroscience and brain-machine interface (BMI) systems, aiding patients with neurological disorders, paralysis, and amputations. However, IMEs often fail to maintain robust signal quality over time, partly due to neuroinflammation caused by vascular damage during insertion. Platelet-inspired nanoparticles (PIN), which possess injury-targeting functions, mimic the adhesion and aggregation of active platelets through conjugated collagen-binding peptides (CBP), von Willebrand Factor-binding peptides (VBP), and fibrinogen-mimetic peptides (FMP).

View Article and Find Full Text PDF

Background: Recent advancements in Alzheimer's disease (AD) biomarker research and AD drug trials prompt reflection on the value and appropriate use of tau-PET in future clinical practice and trials. We therefore conducted a survey among dementia and PET experts worldwide to investigate how they envision the future role of tau-PET in clinical practice and trials.

Method: An online survey was distributed to dementia clinicians and researchers who were invited to participate through personalized emails, social media channels and/or presentations at relevant conferences.

View Article and Find Full Text PDF

Developing Topics.

Alzheimers Dement

December 2024

Washington University in St. Louis, School of Medicine, St. Louis, MO, USA.

Background: In autosomal dominant Alzheimer disease (ADAD), the position of a pathogenic genetic variant within the presenilin-1 (PSEN1) coding sequence influences how amyloid-beta accumulates and how dementia progresses (Joseph-Mathurin et al, 2024). In the first trial of anti-amyloid monoclonal antibodies in individuals at risk for ADAD (Dominantly Inherited Alzheimer Network Trials Unit study 1 [DIAN-TU-001]), gantenerumab demonstrated target engagement but did not meet its primary clinical endpoint (Salloway et al, 2021). Whether the distribution of pathogenic genetic variants within the cohort may have influenced the trial results remains unclear.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Novo Nordisk A/S, Søborg, 2860 Søborg, Denmark.

Background: Phase 3 randomized clinical trials within Alzheimer's Disease (AD) typically last over 18 months. Post-baseline participants can use additional treatment for Alzheimer's disease, potentially impacting the cognitive ability as evaluated by the primary endpoint. Consequently, this could overestimate or underestimate the treatment effect, depending on the distribution of usage between treatment arms.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

GSK, Stevenage, Hertfordshire, United Kingdom.

Background: Progranulin (PGRN), a glycoprotein secreted by microglia and neurons, regulates lysosomal function, neuroinflammation, and has neurotrophic effects. Variants in the granulin gene (GRN) that cause a reduction of PGRN in plasma and cerebrospinal fluid (CSF) are associated with an increased risk of Alzheimer's disease (AD). The sortilin receptor (SORT1) on neurons and microglia regulates PGRN degradation.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!